Pluri (PLUR) Price & Analysis

Compare

976 Followers

PLUR Stock Chart & Stats

$3.45

-$0.22(-4.74%)

At close: Jan 08 4:00 PM EST

$3.45

-$0.22(-4.74%)

Day’s Range― - ―

52-Week Range$2.82 - $7.13

Previous CloseN/A

Volume1.48K

Average Volume (3M)8.39K

Market Cap

$35.38M

Enterprise Value$65.34M

Total Cash (Recent Filing)$12.71M

Total Debt (Recent Filing)$40.78M

Price to Earnings (P/E)―

Beta0.83

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding10,050,743

10 Day Avg. Volume13,380

30 Day Avg. Volume8,388

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)-4.58

Price to Sales (P/S)23.48

P/FCF Ratio-1.58

Enterprise Value/Market Cap1.85

Enterprise Value/Revenue48.80

Enterprise Value/Gross Profit229.27

Enterprise Value/Ebitda-2.51

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthStrong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.

Strategic PartnershipsStrategic partnerships expand Pluri's market reach and provide additional funding, supporting long-term growth and innovation in its product pipeline.

Leadership IncentivesAligning executive incentives with performance goals can drive strategic decision-making and improve operational efficiency, benefiting long-term company performance.

Bears Say

Financial InstabilityFinancial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.

Negative Cash FlowNegative cash flow indicates ongoing operational challenges, which may hinder Pluri's ability to sustain operations and invest in future growth without additional financing.

Profitability ChallengesOngoing profitability challenges with negative margins suggest difficulty in achieving sustainable earnings, impacting long-term financial health and investor confidence.

Pluri News

Pluri secures global IP position with CNIPA for immune cell expansion

Pluri (PLUR) announces that the China National Intellectual Property Administration, CNIPA, has granted Pluri Biotech, a wholly owned...

14d ago

PLUR

Pluri Regains Nasdaq Compliance, Restoring Listing Stability

An update from Pluri ( ($PLUR) ) is now available. On January 20, 2026, Pluri Inc. disclosed it...

2d ago

PLUR

Pluri Faces Nasdaq Noncompliance Notice, Evaluating Listing Options

Pluri ( ($PLUR) ) has issued an announcement. On January 20, 2026, Pluri Inc. disclosed that it had...

1M ago

PLUR

Pluri completes first phase of program with Resbiomed Technologies OOD

Pluri (PLUR) announced the completion of the first phase of its program with Resbiomed Technologies OOD, a European...

1M ago

PLUR

Pluri announces expansion of manufacturing agreement with Remedy Cell

Pluri (PLUR) announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration...

2M ago

PLUR

Pluri Grants RSUs to Executives and Board Members

An update from Pluri ( ($PLUR) ) is now available. On December 4, 2025, Pluri‘s board of directors...

3M ago

PLUR

Pluri appoints Weinstein as Chairman of the Board of Directors

Pluri (PLUR) announced that Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the...

3M ago

PLUR

Pluri announces launch of Cellav Health and Aesthetics

Pluri (PLUR) announces the launch of Cellav Health and Aesthetics, its wholly-owned health and aesthetics subsidiary, focused on...

4M ago

PLUR

Pluri enters series of international collaborations

Pluri (PLUR) entered into a series of significant international collaborations across its foodtech and agtech subsidiaries. These collaborations...

4M ago

PLUR

Pluri Approves Equity Awards for CEO Yaky Yanay

Pluri ( ($PLUR) ) has issued an announcement. On October 15, 2025, Pluri Inc.’s board of directors approved...

5M ago

PLUR

Pluri subsidiary Coffeesai announces strategic collaboration for manufacturing

Pluri (PLUR) announced that Coffeesai, its wholly owned subsidiary developing sustainable cell-based coffee products, has signed an agreement...

5M ago

PLUR

Pluri files to sell 3.425M common shares for holders

17:29 EDT Pluri (PLUR) files to sell 3.425M common shares for holders Published first on TheFly – the...

6M ago

PLUR

Pluri Resolves Nasdaq Compliance Issue with New Director

Pluri ( ($PLUR) ) has shared an announcement. Pluri Inc. faced a compliance issue with Nasdaq’s Audit Committee...

6M ago

PLUR

Pluri Appoints Eitan Ajchenbaum to Board of Directors

An update from Pluri ( ($PLUR) ) is now available. On September 10, 2025, Pluri Inc. appointed Mr....

6M ago

PLUR

PLUR FAQ

What was Pluri’s price range in the past 12 months?

Pluri lowest stock price was $2.82 and its highest was $7.13 in the past 12 months.

What is Pluri’s market cap?

Pluri’s market cap is $35.38M.

When is Pluri’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pluri’s earnings last quarter?

Currently, no data Available

Is Pluri overvalued?

According to Wall Street analysts Pluri’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Pluri pay dividends?

Pluri does not currently pay dividends.

What is Pluri’s EPS estimate?

Pluri’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pluri have?

Pluri has 10,050,743 shares outstanding.

What happened to Pluri’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pluri?

Currently, no hedge funds are holding shares in PLUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pluri

Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.